2012•Unpublished venueRequires access

Acitretin in psoriasis treatment - recommended treat ment regimens

Marta Pastuszka, Andrzej Kaszuba

Open publisher page 4 citations

Abstract

Acitretin is a synthetic retinoid, a pharmacologically active metabolite of etretinate. It is characterized by very favourable pharmacological profile: its period of half-life is approximately 2 days, it is nearly 50 times less lipophilic than etretinate, and its efficacy in the treatment of psoriasis is comparable to etretinate. The mechanism of its action is not yet fully understood, but it is known that acitretin normalizes all processes typical for psoriasis. The paper discusses in details the indications for acitretin, its efficacy in monotherapy and combination therapy, the principles of alternate therapy, and also the most common side effects during treatment. In addition, we clas sify the most important recommendations to be aware of before, during and after treatment.

About this research paper

What this paper is about

Acitretin is a synthetic retinoid, a pharmacologically active metabolite of etretinate. It is characterized by very favourable pharmacological profile: its period of half-life is approximately 2 days, it is nearly 50 times less lipophilic than etretinate, and its efficacy in the treatment of psoriasis is comparable to etretinate. The mechanism of its action is not yet fully understood, but it is known that acitretin normalizes all processes typical for psoriasis. The paper discusses in details the indications for acitretin, its efficacy in monotherapy and combination therapy, the principles of alternate therapy, and also the most common side effects during treatment. In addition, we clas sify the most important recommendations to be aware of before, during and after treatment.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Acitretin is a synthetic retinoid, a pharmacologically active metabolite of etretinate. It is characterized by very favourable pharmacological profile: its period of half-life is approximately 2 days, it is nearly 50 times less lipophilic than etretinate, and its efficacy in the treatment of psoriasis is comparable to etretinate. The mechanism of its action is not yet fully understood, but it is known that acitretin normalizes all processes typical for psoriasis. The paper discusses in details the indications for acitretin, its efficacy in monotherapy and combination therapy, the principles of alternate therapy, and also the most common side effects during treatment. In addition, we clas sify the most important recommendations to be aware of before, during and after treatment.

Key concepts: Etretinate, Acitretin, Psoriasis, Medicine, Pharmacology, Dermatology, Active metabolite, Retinoid

Related papers

Back to paper searchBrowse research topicsOriginal source
Acitretin in psoriasis treatment - recommended treat ment regimens — Research Paper | ScholarLens